Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct;47(10):1343-8.
doi: 10.1016/j.jpsychires.2013.06.017. Epub 2013 Jul 18.

Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder

Sheng-Yu Lee  1 , Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzung Lieh Yeh, Yen Kuang Yang, Ru-Band Lu, Jau-Shyong Hong
Affiliations
Randomized Controlled Trial

Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder

Sheng-Yu Lee et al. J Psychiatr Res. 2013 Oct.

Abstract

Memantine is a noncompetitive NMDA receptor antagonist. As an augmenting agent, it has an antidepressant-like and mood-stabilizing effect. Memantine also reduces binge eating episodes and weight. We investigated whether memantine added on to valproate (VPA) is more effective than VPA alone for treating BP-II depression and improving the patient's metabolic profile. This was a randomized, double-blind, controlled study. BP-II patients undergoing regular VPA treatments were randomly assigned to one of two groups: VPA plus either add-on [1] memantine (5 mg/day) (n = 62) or [2] placebo (n = 73) for 12 weeks. The Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) were used to evaluate clinical response. Height, weight, fasting serum glucose, fasting total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were followed regularly. Multiple linear regressions with generalized estimating equation methods were used to analyze the effects of memantine on clinical performance. There were no significant differences in pre- and post-treatment YMRS and HDRS scores between the VPA + memantine and VPA + placebo groups. Although there were no significant differences in the pre- and post-treatment values of most metabolic indices between the two groups, there was a significant increase of HDL-C (p = 0.009) in the VPA + memantine group compared with the VPA + placebo group. This increase remained significant even after controlling for body mass index (BMI) (p = 0.020). We conclude that add-on memantine plus VPA treatment of BP-II depression increases the blood level of HDL-C even in the absence of change in affective symptoms.

Trial registration: NCT01188148 (https://register.clinicaltrials.gov/), Trial date was from 1st August, 2008 to 31st July, 2012 in National Cheng Kung University and Tri-Service General Hospital.

Keywords: Bipolar II disorder; HDL-C; Memantine; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

All authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Enrollment, randomization, withdrawals, and completion of the 2 treatment phases.
Fig. 2
Fig. 2
Improvement of high density lipoprotein cholesterol (HDL-C) compared with baseline in the valproate (VPA) + memantine and VPA + placebo groups.
See this image and copyright information in PMC

References

    1. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. American Journal of Psychiatry. 1977;134:1227–33. - PubMed
    1. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatric Clinics of North America. 1999;22:517–34. vii. - PubMed
    1. Akiskal HS, Rosenthal RH, Rosenthal TL, Kashgarian M, Khani MK, Puzantian VR. Differentiation of primary affective illness from situational, symptomatic, and secondary depressions. Archives of General Psychiatry. 1979;36:635–43. - PubMed
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorder-IV-TR. 4. Washington: American Psychiatric Association; 2000.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorder-IV-TR. 4. Washington: American Psychiatric Association; 2002.

Publication types

Associated data